<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl1" position="float">
 <label>Table 1</label>
 <caption>
  <p>Baseline characteristics of all randomly assigned patients</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th/>
    <th align="left">
     <bold>CHOP (six cycles; n=43)</bold>
    </th>
    <th align="left">
     <bold>GEM-P (four cycles; n=44)</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="2" align="left">Sex</td>
    <td/>
    <td/>
   </tr>
   <tr>
    <td/>
    <td align="left">Men</td>
    <td align="left">30 (70%)</td>
    <td align="left">32 (73%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Women</td>
    <td align="left">13 (30%)</td>
    <td align="left">12 (27%)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">Age (years; median IQR)</td>
    <td align="left">64 (54–69)</td>
    <td align="left">61 (50–70)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">Aged &gt;60 years</td>
    <td align="left">27 (63%)</td>
    <td align="left">24 (55%)</td>
   </tr>
   <tr>
    <td colspan="4" align="left">IPI score</td>
   </tr>
   <tr>
    <td/>
    <td align="left">0–1</td>
    <td align="left">9 (21%)</td>
    <td align="left">8 (18%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">2–3</td>
    <td align="left">26 (60%)</td>
    <td align="left">25 (57%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">4–5</td>
    <td align="left">8 (19%)</td>
    <td align="left">11 (25%)</td>
   </tr>
   <tr>
    <td colspan="4" align="left">Local histology</td>
   </tr>
   <tr>
    <td/>
    <td align="left">PTCL not otherwise specified</td>
    <td align="left">19 (44%)</td>
    <td align="left">18 (41%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">ALK-negative ALCL</td>
    <td align="left">6 (14%)</td>
    <td align="left">8 (18%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">AITL</td>
    <td align="left">17 (40%)</td>
    <td align="left">17 (39%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">EATL</td>
    <td align="left">1 (2%)</td>
    <td align="left">1 (2%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Hepatosplenic γδ T-cell lymphoma</td>
    <td align="left">0</td>
    <td align="left">0</td>
   </tr>
   <tr>
    <td colspan="4" align="left">Central histology</td>
   </tr>
   <tr>
    <td/>
    <td align="left">PTCL not otherwise specified</td>
    <td align="left">11 (26%)</td>
    <td align="left">10 (23%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">ALK-negative ALCL</td>
    <td align="left">4 (9%)</td>
    <td align="left">4 (9%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">AITL</td>
    <td align="left">22 (51%)</td>
    <td align="left">17 (39%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">EATL</td>
    <td align="left">1 (2%)</td>
    <td align="left">0</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Panniculitis-like T-cell lymphoma</td>
    <td align="left">0</td>
    <td align="left">1 (2%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">PTCL not otherwise specified or panniculitis-like T-cell lymphoma</td>
    <td align="left">0</td>
    <td align="left">1 (2%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">Not assessable</td>
    <td align="left">5</td>
    <td align="left">11 (25%)</td>
   </tr>
   <tr>
    <td colspan="4" align="left">Stage</td>
   </tr>
   <tr>
    <td/>
    <td align="left">I</td>
    <td align="left">1 (2%)</td>
    <td align="left">0</td>
   </tr>
   <tr>
    <td/>
    <td align="left">II</td>
    <td align="left">8 (19%)</td>
    <td align="left">3 (7%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">III</td>
    <td align="left">16 (37%)</td>
    <td align="left">16 (36%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">IV</td>
    <td align="left">18 (42%)</td>
    <td align="left">25 (57%)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">B symptoms present</td>
    <td align="left">26 (60%)</td>
    <td align="left">27 (61%)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">Increased lactate dehydrogenase</td>
    <td align="left">27 (63%)</td>
    <td align="left">27 (61%)</td>
   </tr>
   <tr>
    <td colspan="2" align="left">Extranodal sites present</td>
    <td align="left">25 (58%)</td>
    <td align="left">30 (68%)</td>
   </tr>
   <tr>
    <td colspan="4" align="left">WHO performance status</td>
   </tr>
   <tr>
    <td/>
    <td align="left">0</td>
    <td align="left">17 (40%)</td>
    <td align="left">21 (48%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">1</td>
    <td align="left">19 (44%)</td>
    <td align="left">18 (41%)</td>
   </tr>
   <tr>
    <td/>
    <td align="left">2</td>
    <td align="left">7 (16%)</td>
    <td align="left">5 (11%)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Data are n (%) except where indicated otherwise. CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisolone. GEM-P=gemcitabine, cisplatin, and methylprednisolone. IPI=International Prognostic Index. PTCL=peripheral T-cell lymphoma. ALK-negative ALCL=anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. AITL=angioimmunoblastic T-cell lymphoma. EATL=enteropathy-associated T-cell lymphoma.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
